Optiver Holding
LXEO icon

Optiver Holding’s Lexeo Therapeutics LXEO Stock Holding History

Optiver Holding’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.53K Sell
544
-56
-9% -$303 ﹤0.01% 2241
2026
Q1 		$3.44K Buy
600
+288
+92% +$2.04K ﹤0.01% 1595
2025
Q4 		$3.1K Hold
312
– – ﹤0.01% 1728
2025
Q3 		$2.07K Buy
+312
New +$1.51K ﹤0.01% 2373

Other funds holding LXEO

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Optiver Holding's LXEO Position: Q2 2026 in Review

Optiver Holding reduced its Lexeo Therapeutics (LXEO) stake by 9.3% in Q2 2026, selling an estimated $303 and leaving 544 shares worth $2.53K. The position accounts for ﹤0.01% of the portfolio, ranked #2241.

Optiver Holding first reported a position in LXEO in Q3 2025 and has held it in 4 quarters since. The position peaked at $3.44K in Q1 2026. 141 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • Optiver Holding held 544 shares of Lexeo Therapeutics worth $2.53K as of Q2 2026.
  • Optiver Holding sold 56 Lexeo Therapeutics shares in Q2 2026, an estimated $303.
  • Lexeo Therapeutics made up ﹤0.01% of Optiver Holding's portfolio in Q2 2026, its #2241 holding.
  • Optiver Holding first reported a position in Lexeo Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Optiver Holding's Lexeo Therapeutics position peaked at $3.44K in Q1 2026.
  • 141 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on Optiver Holding's 13F filing for Q2 2026, filed 12 Aug 2026.